Huaren Health: The application for the registration and marketing authorization of Furmaric Acid Voronol Tablets has been accepted
I'm PortAI, I can summarize articles.
Huaren Health's wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application for Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration. This new drug is a potassium ion competitive acid blocker that can effectively inhibit gastric acid secretion without relying on an acidic environment, significantly reducing the occurrence of nighttime gastric acid elevation
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments